Today, Zacks: Alimera Sciences Inc. (ALIM) Given Average Recommendation of “Strong Buy” by Brokerages

Today, Zacks: Alimera Sciences Inc. (ALIM) Given Average Recommendation of “Strong Buy” by Brokerages
Shares of Alimera Sciences Inc. (NASDAQ:ALIM) have earned an average broker rating score of 1.00 (Strong Buy) from the one analysts that provide coverage for the stock, Zacks Investment Research reports. One investment analyst has rated the stock with a strong buy rating. Alimera Sciences’ rating score has improved by 66.7% in the last 90 days as a result of various analysts’ ratings changes.

Analysts have set a twelve-month consensus price target of $3.00 for the company and are anticipating that the company will post ($0.05) earnings per share for the current quarter, according to Zacks. Zacks has also given Alimera Sciences an industry rank of 71 out of 265 based on the ratings given to its competitors.

ALIM has been the topic of a number of recent analyst reports. Cowen and Company reaffirmed a “market perform” rating and set a $2.00 target price on shares of Alimera Sciences in a research note on Friday, August 5th. Zacks Investment Research cut shares of Alimera Sciences from a “buy” rating to a “hold” rating in a research note on Wednesday, October 19th.

In related news, insider Richard S. Eiswirth, Jr. sold 51,471 shares of the business’s stock in a transaction on Thursday, September 15th. The shares were sold at an average price of $1.51, for a total value of $77,721.21. Following the sale, the insider now owns 86,445 shares of the company’s stock, valued at $130,531.95. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Company insiders own 14.00% of the company’s stock.

Hedge funds have recently modified their holdings of the company. Paloma Partners Management Co acquired a new stake in shares of Alimera Sciences during the second quarter valued at $140,000. PNC Financial Services Group Inc. boosted its stake in shares of Alimera Sciences by 107.3% in the third quarter. PNC Financial Services Group Inc. now owns 95,100 shares of the biopharmaceutical company’s stock valued at $142,000 after buying an additional 49,215 shares in the last quarter. Northern Trust Corp boosted its stake in shares of Alimera Sciences by 108.9% in the third quarter. Northern Trust Corp now owns 105,320 shares of the biopharmaceutical company’s stock valued at $157,000 after buying an additional 54,906 shares in the last quarter. Spark Investment Management LLC acquired a new stake in shares of Alimera Sciences during the third quarter valued at $262,000. Finally, Sphera Funds Management LTD. acquired a new stake in shares of Alimera Sciences during the third quarter valued at $299,000. 31.80% of the stock is currently owned by institutional investors.

Alimera Sciences (NASDAQ:ALIM) remained flat at $1.11 on Friday. 46,825 shares of the company’s stock traded hands. Alimera Sciences has a 1-year low of $1.01 and a 1-year high of $5.15. The company’s 50-day moving average is $1.29 and its 200 day moving average is $1.48. The company’s market cap is $72.00 million.

Alimera Sciences (NASDAQ:ALIM) last announced its quarterly earnings data on Wednesday, November 2nd. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by $0.05. The company had revenue of $8.30 million for the quarter, compared to analyst estimates of $10.53 million. Alimera Sciences’s revenue was up 20.3% compared to the same quarter last year. During the same quarter last year, the business earned ($0.21) earnings per share. On average, equities research analysts anticipate that Alimera Sciences will post ($0.54) earnings per share for the current fiscal year.

Alimera Sciences Company Profile

Alimera Sciences, Inc (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through two segments: U.S. and International. The Company focuses on diseases affecting the back of the eye or retina.

Related posts

Leave a Comment